Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER_GOV 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Colorectal Neoplasms 14Stomach Neoplasms 4Esophageal Squamous Cell Carcinoma 4Colonic Neoplasms 4Rectal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Esophageal Neoplasms 3Neoplasms 2Leukemia, Biphenotypic, Acute 2Intestinal Neoplasms 2Gastrointestinal Neoplasms 2Gastrointestinal Diseases 2Digestive System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Diseases 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Mesothelioma, Malignant 1Melanoma 1Malignant Solid Tumour 1Lymphoma, Non-Hodgkin 1Intestinal Diseases 1Endometrial Neoplasms 1Digestive System Diseases 1

Interventions

Oxaliplatin 290Capecitabine 206Fluorouracil 181Cisplatin 168Docetaxel 138S 1 (combination) 132Paclitaxel 121Leucovorin 116Irinotecan 106pembrolizumab 103Trastuzumab 72apatinib 56Nivolumab 56sintilimab 45Drug Therapy 43Surgical Procedures, Operative 37Radiotherapy 37Bevacizumab 37Ramucirumab 34titanium silicide 31Hyperthermic Intraperitoneal Chemotherapy 30Epirubicin 30Carboplatin 30tislelizumab 28Cyclophosphamide 27XELOX 24Tegafur 23Folfox protocol 22Albumin-Bound Paclitaxel 22camrelizumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Stomach Neoplasms × Levoleucovorin × Clear all
NCT06793917 2025-07-20

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Fujian Cancer Hospital

Phase 3 Recruiting
269 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NuCana plc

Phase 1/2 Terminated
19 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Fujian Cancer Hospital

Phase 1/2 Recruiting
51 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06197438 2024-01-09

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

Fujian Cancer Hospital

Phase 2 Unknown
36 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡